Call Us: 1.800.873.5297


EMA Agrees with FDA: Testosterone Therapy Drugs Not for Lifestyle Use

According to a recent report, the EMA has agreed with the FDA that the use of testosterone drugs should be reserved for men whose testosterone levels are low due to a medical condition. An EMA oversight committee said, “Testosterone levels naturally fall somewhat with age, but restoration of these levels in healthy older mean is […]


Testosterone Therapy (Low-T) Lawsuit Update: Direct Filing Order Entered in MDL 2545

On October 24, 2014, The Honorable Matthew F. Kennelly entered an Order allowing for the filing of federal complaints directly into the testosterone therapy multidistrict litigation (MDL 2545) pending in the United States District Court for the Northern District of Illinois. Kristine Kraft, a partner at Schlichter, Bogard & Denton, LLP, has been appointed by […]


FDA May Tighten Restrictions for Testosterone Drugs

CBS reports that the FDA Advisory Committee voted 20-1 that the product labels of popular testosterone drugs should be revised to clearly indicate that these drugs have not been shown to reverse common aging issues, including muscle loss and libido. Members of the Advisory Committee also unanimously agreed that evidence linking cardiovascular events and blood […]


Testosterone Lawsuit Update: FDA Advisory Committee Decides Further Study of Cardiovascular Risks Required

Bloomberg News reports that the members of a Food and Drug Administration (FDA) Advisory Committee unanimously agreed this week that manufacturers of testosterone drugs should further study the potential cardiovascular health risks of testosterone products and who should take these drugs. According to the FDA, the Advisory Committee Meeting was held on September 17, 2014 […]


FDA Warns of Dangerous Testosterone Risks for Men, NBC News Reports

NBC Nightly News reports that “[t]estosterone treatment is a growing multibillion-dollar business, but it presents the risk of life-threatening blood clots.” In the news segment, the NBC reporter comments: “In 2013, doctors wrote 7.5 million prescriptions for testosterone, up from about 4 million in 2009. While treatment for abnormally low testosterone levels is warranted in […]


Schlichter, Bogard & Denton, LLP News: Partner Kristine Kraft Appointed to the Plaintiffs’ Steering Committee in Testosterone Therapy MDL 2545

Kristine Kraft, a partner at Schlichter, Bogard & Denton, LLP, has been appointed to the Plaintiffs’ Steering Committee in the Low-T Multidistrict Litigation (MDL 2545) pending in the Northern District of Illinois (Case Management Order No. 4, In Re: Testosterone Therapy Products Liability Litigation, Case No. 1:14-cv-1748, MDL No. 2545, N.D. Ill.). The Honorable Matthew […]


Low-Testosterone Replacement Therapies Make Cover of Time Magazine: Are They Safe?

The topic of low testosterone (Low-T) replacement therapy drugs will be discussed, along with securing the coveted cover page, in the August 2014 issue of Time Magazine. The magazine will feature an article discussing the $2 Billion testosterone drug industry and detailing the safety concerns centered around Low-T replacement medications. This comes as no surprise […]


Health Canada Warns of Cardiovascular Risks Associated with Testosterone Therapy Drugs

On July 15, 2014, Health Canada warned patients and healthcare professionals of serious and possibly life-threatening cardiovascular risks associated with testosterone replacement therapies. Health Canada recently completed a safety review of low-testosterone products, which revealed that Low-T product use is linked to heart and blood vessel problems, such as heart attack, stroke, pulmonary embolisms (blood […]


Low-T Lawsuit Update (MDL 2545): FDA Weighs Data on Testosterone Drugs and Heart Attack Risk

The U.S. Food and Drug Administration (FDA) has called a special advisory committee meeting to discuss the results of two trials that demonstrated an increased risk of heart attack in men using testosterone replacement drugs. The FDA called the meeting after it required new label changes on all testosterone replacement therapies to warn consumers of […]


FDA Requires Revised Labeling for Testosterone Drugs to Warn of Increased Risk of Blood Clots

On June 20th, the U.S. Food and Drug Administration (FDA) issued a safety warning notifying health care professionals and medical care organizations that it will require manufacturers of approved testosterone products to revise their product labeling to include heightened warnings about the risk of venous blood clots. The previous labeling included the risk of blood […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.